TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24929949

Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir 700/100 mg b.i.d. for 16 days with a single dose of olanzapine 15 mg on Day 13
Number of subjects: 24

Group type: COMPARATOR
Intervention: olanzapine 10 mg alone
Number of subjects: 24
Study: 22292421

Group type: EXPERIMENTAL
Intervention: Behavioural neurocardiac training (with heart rate variability biofeedback)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Autogenic relaxation
Number of subjects: 45
Study: 20827655

Group type: EXPERIMENTAL
Intervention: Slide ergometer
Number of subjects: 7

Group type: COMPARATOR
Intervention: Stationary ergometer
Number of subjects: 7
Study: 17562278

Group type: EXPERIMENTAL
Intervention: 125I radioactive seed implantation
Number of subjects: 20
Study: 15718269

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12442349

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg via 15 min infusion every 3-4 weeks)
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Pamidronate (90 mg via 2 hr infusion)
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg)
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1189
Study: 10456490

Group type: EXPERIMENTAL
Intervention: Full-strength grapefruit juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Half-strength grapefruit juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (200 ml orange juice)
Number of subjects: 10
Study: 8553212

Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted colectomy (LAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 0
Study: 1695310

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 16
Study: 445503

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide alone (1 g/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (500 mg/m2) plus Adriamycin (40 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination regimen (Cyclophosphamide plus Adriamycin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30202898

Group type: EXPERIMENTAL
Intervention: Sequential Monte Carlo adaptation for updating posterior distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More complex statistical models
Number of subjects: 0
Study: 31109746

Group type: EXPERIMENTAL
Intervention: 2-mm hard acrylic, maxillary stabilization-type splint for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment after SF aspiration
Number of subjects: 24
Study: 29878718

Group type: EXPERIMENTAL
Intervention: Double diluted abobotulinum toxin type A (Dysport) (dilution of 15 mL to give 3.33 units per 0.1 mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Common concentration of abobotulinum toxin type A (Dysport) (dilution of 7.5 mL to give 6.67 units per 0.1 mL)
Number of subjects: 10
Study: 27251910

Group type: EXPERIMENTAL
Intervention: Enhanced care with input from a homeless care team
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard care (all management by the hospital‐based clinical team)
Number of subjects: 410
Study: 25260191

Group type: EXPERIMENTAL
Intervention: Individualized parent education intervention (12 sessions)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Monitoring control group (4 sessions of behavioral support)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Both groups (treatment and control)
Number of subjects: 66
Study: 22418908

Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg once daily
Number of subjects: 4020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4020
Study: 20923006

Group type: EXPERIMENTAL
Intervention: Static headspace (s‐HS) at 40 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Static headspace (s‐HS) at 60 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Headspace solid phase micro extraction (HS‐SPME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid‐liquid partition
Number of subjects: 0
Study: 17532102

Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 16314629

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1147
Study: 17083180

Group type: EXPERIMENTAL
Intervention: Chiropractic treatment (8 modes)
Number of subjects: 336
Study: 10634832

Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 924

Group type: COMPARATOR
Intervention: Conventional Ventilation (IMV)
Number of subjects: 924
Study: 8796182

Group type: EXPERIMENTAL
Intervention: High-dose FSH (150 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose FSH
Number of subjects: 0
Study: 1643014

Group type: COMPARATOR
Intervention: Conventional-dose cytarabine (200 mg/m2/d by continuous infusion)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (500 mg/m2 every 12 h)
Number of subjects: 101
Study: 6380981

Group type: EXPERIMENTAL
Intervention: Manual anastomosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stapler anastomosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastomosis at 6 cm from anocutaneous line
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastomosis above 6 cm from anocutaneous line
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastomosis below 6 cm from anocutaneous line
Number of subjects: 0
Study: 31470796

Group type: EXPERIMENTAL
Intervention: K‐Y™ jelly lubrication
Number of subjects: 0
Study: 29326183

Group type: EXPERIMENTAL
Intervention: vNOTES (transvaginal natural orifice transluminal endoscopic surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic treatment (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vNOTES
Number of subjects: 0
Study: 26858219

Group type: EXPERIMENTAL
Intervention: Modified Interlaminar (MIL) approach
Number of subjects: 84

Group type: COMPARATOR
Intervention: Transforaminal (TF) approach
Number of subjects: 84
Study: 25726658

Group type: EXPERIMENTAL
Intervention: Modified Xuefuzhuyutang
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study: 22729800

Group type: EXPERIMENTAL
Intervention: Non-invasive sensory feedback system using air-mediated pressure from silicone pads on the prosthetic hand to the amputation stump.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy non-amputees
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Trans‐radial amputees
Number of subjects: 32
Study: 20018567

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 18351298

Group type: EXPERIMENTAL
Intervention: Patient education (fact sheet explaining importance of reducing IOP and efficacy of bimatoprost)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No intervention (only instructed to instil bimatoprost daily)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Patient education (fact sheet)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bimatoprost therapy
Number of subjects: 106
Study: 15903375

Group type: EXPERIMENTAL
Intervention: Cs-Rr (Cordyceps sinensis and Rhodiola rosea)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12771264

Group type: EXPERIMENTAL
Intervention: Idebenone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 10384851

Group type: EXPERIMENTAL
Intervention: Naseptin antiseptic nasal carrier cream alone (Group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of Naseptin cream and silver nitrate cautery (Group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 64

Group type: COMPARATOR
Intervention: Comparison of age groups in both treatment arms
Number of subjects: 64
Study: 8540598

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 35

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 35
Study: 2050827

Group type: EXPERIMENTAL
Intervention: Procainamide (750 mg IV) with probenecid (2 g orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Procainamide (750 mg IV) without probenecid
Number of subjects: 6
Study: 31781762

Group type: EXPERIMENTAL
Intervention: Letermovir (LET) prophylaxis
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ganciclovir preemptive therapy
Number of subjects: 79
Study: 30962677

Group type: EXPERIMENTAL
Intervention: Aprocitentan 100 mg once a day (qd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg and above
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprocitentan up to 10 µg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprocitentan (single and multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprocitentan (100 mg qd)
Number of subjects: 0
Study: 28104204

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 110
Study: 25624076

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.3mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Morphine (0.1mg/kg)
Number of subjects: 45
Study: 23266359

Group type: EXPERIMENTAL
Intervention: 8mg fesoterodine tablet formulation (test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 8mg fesoterodine tablet formulation (reference)
Number of subjects: 12
Study: 22145774

Group type: EXPERIMENTAL
Intervention: Fractionated pea flour (FPF)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Whole yellow pea flour (WPF)
Number of subjects: 23

Group type: COMPARATOR
Intervention: White wheat flour (WF)
Number of subjects: 23
Study: 19699846

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 569

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 569
Study: 17605561

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 2481
Study: 15472806

Group type: EXPERIMENTAL
Intervention: Anidulafungin (100 mg on day 1, followed by 50 mg per day)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Fluconazole (200 mg on day 1, followed by 100 mg per day)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 601

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 601
Study: 11520994

Group type: EXPERIMENTAL
Intervention: Nutritional rehabilitation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nutritional status assessment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Feeding skill score assessment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Parental awareness assessment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of feeding problems in cases with and without seizures
Number of subjects: 100
Study: 9782437

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ondansetron hydrochloride
Number of subjects: 45
Study: 7838909

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3078909

Group type: EXPERIMENTAL
Intervention: Fiorinal with Codeine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fiorinal alone
Number of subjects: 154

Group type: COMPARATOR
Intervention: Codeine alone
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 30297162

Group type: EXPERIMENTAL
Intervention: Cocaine deprivation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Participants without psychiatric conditions
Number of subjects: 22
Study: 28817424

Group type: EXPERIMENTAL
Intervention: TEE simulator training for 4 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lecture-based training only (Control)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Expert group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: TEE simulator training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 25775072

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 60
Study: 23088300

Group type: EXPERIMENTAL
Intervention: Active paraplegic group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sedentary paraplegic group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 21082870

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Gd‐DTPA‐BMA
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 73
Study: 19074619

Group type: EXPERIMENTAL
Intervention: External focus (focusing on the disk)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Internal focus (focusing on reducing movements of their feet)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no attentional focus instructions)
Number of subjects: 14
Study: 17132410

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric banding (GB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopic isolated sleeve gastrectomy (SG)
Number of subjects: 80
Study: 15310562

Group type: EXPERIMENTAL
Intervention: Proprioceptive balance board training program
Number of subjects: 116

Group type: COMPARATOR
Intervention: Normal training routine (Control)
Number of subjects: 116
Study: 11748787

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg/day
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/day
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 206
Study: 9265425

Group type: EXPERIMENTAL
Intervention: Coated catheters with minocycline and rifampin
Number of subjects: 281

Group type: COMPARATOR
Intervention: Uncoated catheters
Number of subjects: 281
Study: 8489556

Group type: EXPERIMENTAL
Intervention: MDL 72974A (doses > or = 0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDL 72974A (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDL 72974A (single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDL 72974A
Number of subjects: 0
Study: 3435099

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29220524

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Varenicline and Bupropion
Number of subjects: 176
Study: 28074483

Group type: EXPERIMENTAL
Intervention: Generalised estimating equations with independence working correlation structure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalised estimating equations with exchangeable working correlation structure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster randomisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual randomisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomisation to opposite treatment groups
Number of subjects: 0
Study: 26079259

Group type: EXPERIMENTAL
Intervention: Gemstone Spectral Imaging (GSI) with 300mgI/kg contrast material (group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional 120 kVp tube voltage with 450mgI/kg contrast material (group B)
Number of subjects: 47
Study: 23561927

Group type: EXPERIMENTAL
Intervention: Outpatient priming
Number of subjects: 208

Group type: COMPARATOR
Intervention: Inpatient priming
Number of subjects: 208
Study: 21181960

Group type: EXPERIMENTAL
Intervention: Various definitions of mixed urinary incontinence (MUI) based on baseline incontinence measures (MESA questionnaire, Urogenital Distress Inventory, 7-day urinary diary)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Low threshold symptom-based definitions of MUI
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Baseline measures of urinary incontinence severity
Number of subjects: 307
Study: 19808853

Group type: EXPERIMENTAL
Intervention: Exercise training with weight loss (EWL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Caloric restriction with weight loss (CR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Exercise training without weight loss (EX)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 34
Study: 17205304

Group type: EXPERIMENTAL
Intervention: Drinking solution (formulation 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Capsule formulation 2B
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Capsule formulation 2C
Number of subjects: 10
Study: 15229119

Group type: COMPARATOR
Intervention: Dietary antioxidant index (quintiles)
Number of subjects: 27111
Study: 12270860

Group type: COMPARATOR
Intervention: Tissue angiogenesis in patients without ischemic complications (score: 5.69+/‐0.6)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Tissue angiogenesis in patients with strong acute phase response (score: 5.31+/‐0.6)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Serum angiogenic activity in patients without ischemic events (optical density x1000, 270+/‐15)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Serum angiogenic activity in patients without ischemic events (107+/‐5 relative units)
Number of subjects: 69

Group type: COMPARATOR
Intervention: In vivo full angiogenic activity tested in the chick chorioallantoic membrane
Number of subjects: 69
Study: 9832300

Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg single dose
Number of subjects: 24
Study: 8607318

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopentone 5.0 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopentone 6.0 mg/kg
Number of subjects: 120
Study: 2693440

Group type: EXPERIMENTAL
Intervention: Gugulipid (500 mg tds for 12 weeks after 8 weeks of diet and placebo)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Clofibate
Number of subjects: 205
Study: 324487

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29630416

Group type: EXPERIMENTAL
Intervention: Hatha Yoga intervention for 8 weeks
Number of subjects: 0
Study: 28260223

Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5‐mg tablets and pregabalin 75‐mg capsules bid (Group A)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Solifenacin 5‐mg tablets (Group B)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Pregabalin 75‐mg capsules bid (Group C)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 500
Study: 26282525

Group type: EXPERIMENTAL
Intervention: Green Eating (GE) Project intervention
Number of subjects: 608

Group type: COMPARATOR
Intervention: Control group (non-treatment)
Number of subjects: 608
Study: 22626910

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Anxious patients
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Multivariate analyses for depressed patients
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Multivariate analyses for anxious patients
Number of subjects: 275

Group type: COMPARATOR
Intervention: Sociodemographic factors
Number of subjects: 275

Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 275
Study: 21204963

Group type: EXPERIMENTAL
Intervention: Nurse-led cardiovascular risk factor intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Routine diabetes clinic attendance
Number of subjects: 81
Study: 17509580

Group type: EXPERIMENTAL
Intervention: Estro-progestin treatment (2 mg of hemihydrate E(2) and 10 mg of dydrogesterone in a continuous sequential regimen)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16429427

Group type: EXPERIMENTAL
Intervention: Montelukast taken in the morning for 2 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Montelukast taken in the evening for 2 weeks
Number of subjects: 24
Study: 12768153

Group type: EXPERIMENTAL
Intervention: Oxiplex/SP Gel (1-3 mL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 34
Study: 10681072

Group type: EXPERIMENTAL
Intervention: Mibefradil (50-100 mg)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg)
Number of subjects: 324
Study: 9501335

Group type: EXPERIMENTAL
Intervention: Group A (0.15-0.17 mg/m3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B (0.03-0.08 mg/m3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C (0.02-0.03 mg/m3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-exposed)
Number of subjects: 60
Study: 1439620

Group type: EXPERIMENTAL
Intervention: Arthrotec (50 mg diclofenac and 200 micrograms misoprostol)
Number of subjects: 455

Group type: COMPARATOR
Intervention: 50 mg diclofenac (control)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Both treatment groups (Arthrotec and diclofenac)
Number of subjects: 455
Study: 3093827

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 30024627

Group type: EXPERIMENTAL
Intervention: Oral vitamin A soft capsules for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anti‐inflammatory therapy and aerosol inhalation
Number of subjects: 60
Study: 26162646

Group type: EXPERIMENTAL
Intervention: Daikenchuto (15.0 g/day, 5 g three times a day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88